RT Journal Article
T1 Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.
A1 Falco, Agustín
A1 de Oliveira, Thiago Bueno
A1 Cacicedo, Jon
A1 Ospina, Aylen Vanessa
A1 Ticona, Miguel Ángel
A1 Galindo, Héctor
A1 Pereira, Marcos David
A1 Aguilar-Ponce, José Luis
A1 Rueda-Domínguez, Antonio
A1 Soria, Tannia
A1 Taberna, Miren
A1 Iglesias, Lara
A1 Sowley, Taysser
A1 Mesía, Ricard
A1 TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer), 
K1 age
K1 cisplatin
K1 comorbidities
K1 contraindication
K1 frailty
K1 toxicity
AB Cisplatin is the standard of treatment for squamous cell carcinoma of the head and neck (SCCHN) that has demonstrated efficacy, either in locally advanced disease when combined with radiotherapy at high doses, or in metastatic/recurrent disease when combined with other agents. However, the usual toxicities related to cisplatin, such as neurotoxicity, nephrotoxicity, ototoxicity, and hematologic toxicities, especially when high doses have been administered, have important implications in the patients' quality of life. The decision to administer cisplatin depends on several patient factors, such as age, performance status, weight loss, comorbidities, previous toxicities, chronic viral infection, or even the current SARS-CoV-2 pandemic. In order to establish recommendations for the management of patients with SCCHN, a group of experts in medical and radiation oncology from Spain and Latin-American discussed how to identify patients who are not candidates for cisplatin to offer them the most suitable therapeutic alternative.
SN 1179-1322
YR 2021
FD 2021-08-26
LK https://hdl.handle.net/10668/26712
UL https://hdl.handle.net/10668/26712
LA en
DS RISalud
RD Apr 11, 2025